<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190004</url>
  </required_header>
  <id_info>
    <org_study_id>IEC/2017</org_study_id>
    <nct_id>NCT04190004</nct_id>
  </id_info>
  <brief_title>Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia</brief_title>
  <official_title>Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health and Neuro Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of 40IU of intranasal vasopressin on cooperative behavior
      in patients with schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>After completion of clinical assessments all subjects will receive either 40 IU of vasopressin or saline in counterbalanced order on two separate days and perform the behavioral tasks</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Performance in Dictator game</measure>
    <time_frame>60 minutes</time_frame>
    <description>Amount of money shared in dictator game</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance in stag hunt game</measure>
    <time_frame>60 minutes</time_frame>
    <description>Security level in stag hunt game</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressins</intervention_name>
    <description>40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced</description>
    <arm_group_label>vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-45 years

          -  Diagnosed as Schizophrenia or Schizophreniform disorder as per DSM IV TR

          -  At least 7 years of formal education

          -  MOCA score &gt;24

        Exclusion Criteria:

          -  Diagnoses of SIADH, Diabetes Insipidus

          -  Substance dependence in the past 12 months, excluding nicotine dependence

          -  Current comorbid axis 1 psychiatric disorder

          -  Hypersensitivity or previous allergy to Vasopressin

          -  Serious medical or neurological illness which may interfere with assessment and
             administration of vasopressin

          -  Hypertension

          -  Impaired renal functions based on serum creatinine above 1.5

          -  Electrolyte imbalance

          -  Receiving ECT or has received ECT in the past 8 weeks

          -  Clinical history of mental retardation

          -  Pregnancy â€¢ Lactation

          -  Risk of harm to self or others

          -  Any significant nasal pathology which may hinder the intranasal absorption of the drug

          -  Hearing or visual impairment that significantly affects the comprehension and
             execution of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Mental Health and Neurosciecnes</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health and Neuro Sciences, India</investigator_affiliation>
    <investigator_full_name>Dr Naren P Rao</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

